Epocrates, Inc. Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Glancy Binkow & Goldberg LLP
January 07 2013 - 12:13PM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims against the Board of Directors of
Epocrates, Inc. (“Epocrates” or the “Company”) (NASDAQ: EPOC)
related to the proposed acquisition of the Company by Athenahealth.
The transaction is valued at approximately $293 million or $11.75
per share.
This investigation concerns whether the Board of Directors of
Epocrates breached their fiduciary duties to stockholders by
failing to adequately shop the Company before agreeing to enter
into the proposed transaction, and whether the Company has
disclosed all material information to shareholders about the
transaction. The Company has seen substantial recent growth. Its
share price has skyrocketed from $6.93 on July 24, 2012 to $11.74
on September 27, 2012. Further, at least one analyst has set a
target price for the Company’s stock at $15.00 per share.
If you are a shareholder of Epocrates, if you have information
or would like to learn more about our investigation, or if you wish
to discuss these matters or have any questions concerning this
announcement or your rights or interests with respect to these
matters, please contact Louis Boyarsky, Esquire, Glancy Binkow
& Goldberg LLP, 1925 Century Park East, Suite 2100, Los
Angeles, CA 90067, by telephone at (310) 201-9150 or Toll Free at
(888) 773-9224 or by email to shareholders@glancylaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Epocrates, Inc. (MM) (NASDAQ:EPOC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Epocrates, Inc. (MM) (NASDAQ:EPOC)
Historical Stock Chart
From Jul 2023 to Jul 2024